Impact of the passive immunization campaign with nirsevimab in 2023-24 in Castellón. Final results.

Enfermedades infecciosas y microbiologia clinica (English ed.) Pub Date : 2025-02-06 DOI:10.1016/j.eimce.2025.01.006

Eulalia Gregori-García, Juan Carlos Gascó-Laborda, Lledó Lluch-Bacas, Oscar Pérez-Olaso, Iris Gómez-Alfaro, Juan B Bellido-Blasco

{"title":"Impact of the passive immunization campaign with nirsevimab in 2023-24 in Castellón. Final results.","authors":"Eulalia Gregori-García, Juan Carlos Gascó-Laborda, Lledó Lluch-Bacas, Oscar Pérez-Olaso, Iris Gómez-Alfaro, Juan B Bellido-Blasco","doi":"10.1016/j.eimce.2025.01.006","DOIUrl":null,"url":null,"abstract":"Introduction: In the 2023-2024 season, systematic immunization with the monoclonal antibody nirsevimab was recommended in Spain. The impact that this immunization program had on the target population of the program is analyzed.Methods: Pre-post ecological study comparing 2023-24 vs 2022-23 season. The variation in incidence is described by age groups (0-5, 6-11 and 12-59 months) and hospitalization. Incidence rates were calculated and relative risks (RR) were estimated for each group.Results: The results were very heterogeneous depending on the age group. In children 0-5 months old the RR was 0.16 (0.10-0.25); in those aged 6-11 months, RR of 0.90 (0.56-1.42); and in those aged 12-59 months, RR 1.36 (1.06-1.74). The greatest decrease in risk was in hospitalized children under 6 months, RR 0.13 (0.07-0.22).Conclusion: The results support the positive impact that this campaign had, especially on hospitalizations.","PeriodicalId":72916,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica (English ed.)","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Enfermedades infecciosas y microbiologia clinica (English ed.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.eimce.2025.01.006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: In the 2023-2024 season, systematic immunization with the monoclonal antibody nirsevimab was recommended in Spain. The impact that this immunization program had on the target population of the program is analyzed.

Methods: Pre-post ecological study comparing 2023-24 vs 2022-23 season. The variation in incidence is described by age groups (0-5, 6-11 and 12-59 months) and hospitalization. Incidence rates were calculated and relative risks (RR) were estimated for each group.

Results: The results were very heterogeneous depending on the age group. In children 0-5 months old the RR was 0.16 (0.10-0.25); in those aged 6-11 months, RR of 0.90 (0.56-1.42); and in those aged 12-59 months, RR 1.36 (1.06-1.74). The greatest decrease in risk was in hospitalized children under 6 months, RR 0.13 (0.07-0.22).

Conclusion: The results support the positive impact that this campaign had, especially on hospitalizations.

查看原文